Cargando…

Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome

Monoclonal antibodies are currently used in the treatment of neoplastic, hematological, or inflammatory diseases, a practice that is occasionally associated with a variety of systemic and cutaneous adverse events. Cardiac adverse events include cardiomyopathy, ventricular dysfunction, arrhythmias, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kounis, Nicholas G, Soufras, George D, Tsigkas, Grigorios, Hahalis, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203633/
https://www.ncbi.nlm.nih.gov/pubmed/25340003
http://dx.doi.org/10.4161/onci.27987
_version_ 1782340414188027904
author Kounis, Nicholas G
Soufras, George D
Tsigkas, Grigorios
Hahalis, George
author_facet Kounis, Nicholas G
Soufras, George D
Tsigkas, Grigorios
Hahalis, George
author_sort Kounis, Nicholas G
collection PubMed
description Monoclonal antibodies are currently used in the treatment of neoplastic, hematological, or inflammatory diseases, a practice that is occasionally associated with a variety of systemic and cutaneous adverse events. Cardiac adverse events include cardiomyopathy, ventricular dysfunction, arrhythmias, arrests, and acute coronary syndromes, such as acute myocardial infarction and vasospastic angina pectoris. These events generally follow hypersensitivity reactions including cutaneous erythema, pruritus chills, and precordial pain. Recently, IgE specific for therapeutic monoclonal antibodies have been detected, pointing to the existence of hypersensitivity and Kounis hypersensitivity-associated syndrome. Therefore, the careful monitoring of cardiovascular events is of paramount importance in the course of monoclonal antibody-based therapies. Moreover, further studies are needed to elucidate the pathophysiology of cardiovascular adverse events elicited by monoclonal antibodies and to identify preventive, protective, and therapeutic measures.
format Online
Article
Text
id pubmed-4203633
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-42036332015-02-14 Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome Kounis, Nicholas G Soufras, George D Tsigkas, Grigorios Hahalis, George Oncoimmunology Point of View Monoclonal antibodies are currently used in the treatment of neoplastic, hematological, or inflammatory diseases, a practice that is occasionally associated with a variety of systemic and cutaneous adverse events. Cardiac adverse events include cardiomyopathy, ventricular dysfunction, arrhythmias, arrests, and acute coronary syndromes, such as acute myocardial infarction and vasospastic angina pectoris. These events generally follow hypersensitivity reactions including cutaneous erythema, pruritus chills, and precordial pain. Recently, IgE specific for therapeutic monoclonal antibodies have been detected, pointing to the existence of hypersensitivity and Kounis hypersensitivity-associated syndrome. Therefore, the careful monitoring of cardiovascular events is of paramount importance in the course of monoclonal antibody-based therapies. Moreover, further studies are needed to elucidate the pathophysiology of cardiovascular adverse events elicited by monoclonal antibodies and to identify preventive, protective, and therapeutic measures. Landes Bioscience 2014-02-14 /pmc/articles/PMC4203633/ /pubmed/25340003 http://dx.doi.org/10.4161/onci.27987 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Point of View
Kounis, Nicholas G
Soufras, George D
Tsigkas, Grigorios
Hahalis, George
Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome
title Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome
title_full Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome
title_fullStr Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome
title_full_unstemmed Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome
title_short Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome
title_sort adverse cardiac events to monoclonal antibodies used for cancer therapy: the risk of kounis syndrome
topic Point of View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203633/
https://www.ncbi.nlm.nih.gov/pubmed/25340003
http://dx.doi.org/10.4161/onci.27987
work_keys_str_mv AT kounisnicholasg adversecardiaceventstomonoclonalantibodiesusedforcancertherapytheriskofkounissyndrome
AT soufrasgeorged adversecardiaceventstomonoclonalantibodiesusedforcancertherapytheriskofkounissyndrome
AT tsigkasgrigorios adversecardiaceventstomonoclonalantibodiesusedforcancertherapytheriskofkounissyndrome
AT hahalisgeorge adversecardiaceventstomonoclonalantibodiesusedforcancertherapytheriskofkounissyndrome